⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13282655 | 0.76 | — | — | |
| SCHEMBL13433723 | 0.74 | MAPT (0.32) | — | |
| SCHEMBL19437239 | 0.71 | — | — | |
| SCHEMBL9070074 | 0.71 | — | — | |
| SCHEMBL18999265 | 0.70 | — | — | |
| SCHEMBL268792 | 0.66 | — | — | |
| SCHEMBL15070886 | 0.64 | — | — | |
| Ammonia Solution, Strong SCHEMBL27345029 | 0.64 | — | — | |
| SCHEMBL10765496 | 0.63 | — | — | |
| SCHEMBL20362519 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| EP-3087060-B1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-9815796-B2 | Pyrimidone carboxamide compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| EP-2545042-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-13 | — | — | US | disclosed |
| US-8309558-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-8148382-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-20 | — | — | US | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-7994171-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |